Centre for Advanced Imaging (CAI), Australian Institute for Bioengineering and Nanotechnology (AIBN) and ARC Training Centre for Innovation in Biomedical Imaging Technology, The University of Queensland, Brisbane, Queensland 4072, Australia
Auto-generated profile, based on publicly available information
Saikat Ghosh
Centre for Advanced Imaging (CAI), Australian Institute for Bioengineering and Nanotechnology (AIBN) and ARC Training Centre for Innovation in Biomedical Imaging Technology, The University of Queensland, Brisbane, Queensland 4072, Australia
Pre-targeting of bispecific antibodies is probed to enhance tumour retention while limiting clearance of administered multifunctional branched PEGylated nanomedicines. The temporal influence of pre-targeting on polymer interaction with tumour cells and tissue is explored using in vitro assays through to preclinical validation.
Covalent DFOB-DOTA dual chelator (‘D2’) binds 89 Zr (DFOB) and 177 Lu (DOTA) regio-selectively enabling 89 Zr– 177 Lu pairing as a novel cancer-targeting theranostic.
Covalent conjugation of a biologically stable polymerto a therapeuticprotein, e.g., an antibody, holds many benefits such as prolongedplasma exposure of the protein and improved tumor uptake. Generationof defined conjugates is advantageous in many applications, and arange of site-selective conjugation methods have been reported. Manycurrent coupling methods lead to dispersity in coupling efficiencieswith subsequent conjugates of less-well-defined structure, which impactsreproducibility of manufacture and ultimately may impact successfultranslation to treat or image diseases. We explored designing stable,reactive groups for polymer conjugation reactions that would leadto conjugates through the simplest and most abundant residue on mostproteins, the lysine residue, yielding conjugates in high purity anddemonstrating retention of mAb efficacy through surface plasmon resonance(SPR), cell targeting, and in vivo tumor targeting.We utilized squaric acid diesters as coupling agents for selectiveamidation of lysine residues and were able to selectively conjugateone, or two, high-molecular-weight polymers to a therapeutically relevantantibody, 528mAb, that subsequently retained full binding specificity.Water-soluble copolymers of N-(2-hydroxypropyl) methacrylamide(HPMA) and N-isopropylacrylamide (NIPAM) were preparedby Reversible Addition-Fragmentation chain-Transfer (RAFT)polymerization and we demonstrated that a dual-dye-labeled antibody-RAFTconjugate (528mAb-RAFT) exhibited effective tumor targeting in modelbreast cancer xenografts in mice. The combination of the precise andselective squaric acid ester conjugation method, with the use of RAFTpolymers, leads to a promising strategic partnership for improvedtherapeutic protein-polymer conjugates having a very-well-definedstructure.
31 January 2022 in Expert Opinion on Biological Therapy
Glypican-1 (GPC-1) is a heparan sulfate proteoglycan (HSPG) overexpressed in multiple cancers. Multiple studies indicate the prominence of this cancer biomarker with significant diagnostic and therapeutic potential. Recent advances in monoclonal antibody (mAb)-based biopharmaceuticals targeting GPC-1 show promise toward managing GPC-1-positive solid tumors clinically. This review addresses GPC-1 targeting antibodies for cancer therapy, in preclinical and clinical development. Current and emerging development of different anti-GPC-1 antibody formats based on mechanism of action and application are also discussed. Clinical development of novel anti-GPC-1 antibody-based formats is still in its early days. Using the patented anti-GPC-1 Miltuximab® as a case study, we have made an attempt to illustrate a pathway for preclinical to clinical translation, which could be useful for newer GPC-1 targeting immunotherapy agents.
Purpose: Receptor CUB domain–containing protein 1 (CDCP1) was evaluated as a target for detection and treatment of breast cancer. Experimental Design: CDCP1 expression was assessed immunohistochemically in tumors from 423 patients [119 triple-negative breast cancer (TNBC); 75 HER2+; and 229 ER+/HER2−, including 228 primary tumors and 229 lymph node and 47 distant metastases). Cell cytotoxicity induced in vitro by a CDCP1-targeting antibody-drug conjugate (ADC), consisting of the human/mouse chimeric antibody ch10D7 and the microtubule disruptor monomethyl auristatin E (MMAE), was quantified, including in combination with HER-targeting ADC trastuzumab emtansine (T-DM1). Detection of CDCP1-expressing primary and metastatic xenografts in mice was examined by PET–CT imaging using zirconium-89–labeled ch10D7. The impact of ch10D7-MMAE on tumor burden and survival in vivo, including in combination with T-DM1, was quantified in cell line and patient-derived xenograft mouse models. Results: CDCP1 is expressed predominantly on the surface of malignant cells of 70% of TNBC, 80% of HER2+ tumors, and increases in ER+/HER2− tumors from 44.9% in primary tumors to 56.4% in lymph node metastases and 74.3% in distant metastases. PET-CT imaging with zirconium-89–labeled ch10D7 is effective for the detection of primary and metastatic CDCP1-expressing TNBC in mice. ADC ch10D7-MMAE kills CDCP1-expressing cells in vitro and controls primary and metastatic TNBC xenografts in mice, conferring significant survival advantages over chemotherapy. It compares favorably to T-DM1 in vivo, and ch10D7-MMAE combined with T-DM1 showed the most potent efficacy, markedly reducing tumor burden of CDCP1+/HER2+ xenografts and prolonging mouse survival, compared with T-DM1 or ch10D7. Conclusions: CDCP1-directed molecular imaging has the potential to identify aggressive breast cancers for CDCP1-targeted treatment.